Phynova files patent applications, names new COO and CMO

By Lisa Kerner

Charlotte, N.C., July 12 - Phynova Group plc said it filed two patent applications in the United Kingdom covering its obesity product, PYN-22, and its hepatitis C product, PYN-18.

Both PYN-22 and PYN-18 comprise a purified botanical drug substance (BDS) from a single plant species used as a medicinal herb.

The patent claims cover the broad range of chemical contents of the BDS, the discovery of the potent activity against obesity and pharmaceutical dosage forms containing the BDS.

In addition, the patent provides protection for PYN-18 as a stand-alone therapeutic agent and as a botanical drug in combination with other drugs, such as alpha-interferon.

Phynova also announced the appointment of Stephen Marshall as chief operating officer and David Galloway as chief medical officer.

The company signed a letter of intent with a leading international clinical research organization related to a phase 2b study of Phynova's PYN-17 for the treatment of hepatitis C symptoms.

Based in Oxford, England, Phynova develops drugs derived from Chinese medicines targeting viral and metabolic diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.